Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.
Biochem/physiol Actions
Potent Selective serotonin reuptake inhibitor (SSRI); used in treatment of premature ejaculation
Potent and selective SSRI
Dapoxetine is capable of blocking recombinant Kv4.3 potassium voltage-gated channels. It is considered as safe.
Features and Benefits
This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
To assess both the acceptance and the discontinuation rates from dapoxetine, the first oral pharmacological agent indicated for the treatment of premature ejaculation (PE). One hundred twenty consecutive potent patients (mean age 40.3 years; range 18-63 years) seeking medical treatment
Advances in therapy, 36(8), 2096-2105 (2019-05-31)
Factors that impact the pharmacokinetics of dapoxetine, a 5-HT selective reuptake inhibitor used for the treatment of premature ejaculation, have not been clearly identified. This study aimed to evaluate the effects of consumption of a high-fat meal and cytochrome P450
The journal of sexual medicine, 8(2), 524-539 (2010-11-10)
Dapoxetine has been evaluated for the on-demand treatment of premature ejaculation (PE) in five phase 3 studies in various populations worldwide and has recently been approved in several countries. To present integrated efficacy and safety data from phase 3 trials